Japan embraces global trials to cut drug lag
This article was originally published in Scrip
Executive Summary
As Japan struggles to address its continuing drug lag problem, regulatory authorities there are actively encouraging a shift away from bridging studies towards simultaneous regional and global clinical trials, aided by increased acceptance of foreign clinical data, a recent meeting in Tokyo heard.